Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
10.19428/j.cnki.sjpm.2022.21816
- VernacularTitle:上海市13价肺炎球菌多糖结合疫苗联合接种的安全性分析
- Author:
Shoufei YANG
1
;
Jiechen LIU
1
;
Zhuoying HUANG
1
;
Qingrui BAI
1
;
Xiang GUO
1
;
Jia REN
1
Author Information
1. Shanghai Municipal Center for Disease Control and Prevention， Shanghai 200336， China
- Publication Type:Journal Article
- Keywords:
13-valent pneumococcal polysaccharide conjugate vaccine;
simultaneous vaccination;
adverse event following immunization;
safety
- From:
Shanghai Journal of Preventive Medicine
2022;34(8):751-755
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo compare the incidence of adverse events following immunization （AEFI） between vaccination with 13-valent pneumococcal polysaccharide conjugate vaccine （PCV13） alone and with other vaccines at the same time. MethodsWe obtained PCV13 vaccination adverse reaction reports for children vaccinated in Shanghai between 2017‒2021 from the National Immunization Program Information Management System and collected the information and the data of children vaccinated with PCV13 from The Shanghai vaccination information system. We compared the incidence of adverse reactions between stand-alone and simultaneous vaccination. ResultsA total of 11 175 PCV13 AEFI cases after stand-alone vaccination and 215 PCV13 AEFI cases after simultaneous vaccination were reported during 2017‒2021 in Shanghai， and the incidence rates were 1 252.34/105 and 1 455.75/105， respectively. ORV was the one mostly vaccinated with PCV13 at the same time， and the AEFI incidence was 1 706.67/105. The most reported symptom was fever after PCV13 vaccination， no matter by stand-alone and simultaneous vaccination with the respective incidence rates of 876.69/105 and 1 442.21/105. ConclusionIn general， PCV13 vaccinated with other vaccines at the same time slightly increases the incidence of AEFI.
